Product Description
Mechanisms of Action: NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Incyte
Company Location: Eastern America
Company CEO: Hervé Hoppenot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acquired Immunodeficiency Syndrome|HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-000096-16 |
DECLARE 1 | P2 |
Completed |
HIV Infections |
2006-03-22 |
2022-03-12 |
Treatments |
|
NCT00300573 |
DECLARE | P2 |
Terminated |
Acquired Immunodeficiency Syndrome|HIV Infections |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|